Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Teva
Citi
Deloitte
Julphar
UBS
Cipla
Accenture
Federal Trade Commission

Generated: February 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VINCASAR PFS

« Back to Dashboard

Clinical Trials for Vincasar Pfs

Trial ID Title Status Sponsor Phase Summary
NCT00390793 Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive ALL Active, not recruiting Bristol-Myers Squibb Phase 2 The goal of this clinical research study is to find out if intensive chemotherapy combined with dasatinib, followed by maintenance therapy, can help to control ALL with the Ph chromosome and/or BCR-ABL. The safety of this treatment will also be studied.
NCT00390793 Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive ALL Active, not recruiting M.D. Anderson Cancer Center Phase 2 The goal of this clinical research study is to find out if intensive chemotherapy combined with dasatinib, followed by maintenance therapy, can help to control ALL with the Ph chromosome and/or BCR-ABL. The safety of this treatment will also be studied.
NCT02043587 Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma Recruiting Sigma Tau Pharmaceuticals, Inc. Phase 2 The objective of this protocol is to improve survival for adults with acute lymphoblastic leukemia or acute lymphoblastic lymphoma by reducing systemic and central nervous system (CNS) relapse with acceptable toxicity using intensive chemotherapy with liposomal cytarabine (Depocyt®) CNS prophylaxis.
NCT02043587 Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma Recruiting University of California, San Diego Phase 2 The objective of this protocol is to improve survival for adults with acute lymphoblastic leukemia or acute lymphoblastic lymphoma by reducing systemic and central nervous system (CNS) relapse with acceptable toxicity using intensive chemotherapy with liposomal cytarabine (Depocyt®) CNS prophylaxis.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Vincasar Pfs

Condition Name

Condition Name for Vincasar Pfs
Intervention Trials
High Grade B-Cell Lymphoma, Not Otherwise Specified 2
CD20 Positive 2
Aggressive Non-Hodgkin Lymphoma 2
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Vincasar Pfs
Intervention Trials
Lymphoma 7
Lymphoma, Non-Hodgkin 5
Precursor Cell Lymphoblastic Leukemia-Lymphoma 5
Leukemia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Vincasar Pfs

Trials by Country

Trials by Country for Vincasar Pfs
Location Trials
United States 39
Tanzania 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Vincasar Pfs
Location Trials
Illinois 3
Pennsylvania 3
Ohio 2
North Carolina 2
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Vincasar Pfs

Clinical Trial Phase

Clinical Trial Phase for Vincasar Pfs
Clinical Trial Phase Trials
Phase 3 2
Phase 2/Phase 3 1
Phase 2 6
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Vincasar Pfs
Clinical Trial Phase Trials
Not yet recruiting 6
Recruiting 6
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Vincasar Pfs

Sponsor Name

Sponsor Name for Vincasar Pfs
Sponsor Trials
National Cancer Institute (NCI) 10
Children's Oncology Group 3
Northwestern University 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Vincasar Pfs
Sponsor Trials
Other 15
NIH 10
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Teva
Harvard Business School
Covington
AstraZeneca
Fish and Richardson
Medtronic
Cantor Fitzgerald
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.